Focal therapies are new options for the treatment of localized prostate cancer. Vascular-targeted photodynamic therapy (VTP) with WST11 is one of these options. The aim of this treatment is to destroy a targeted area of the prostate by the associated action of the WST11 drug, light exposure and oxygen. The procedure is performed under general anesthesia. Fibers are introduced trans-perineally in the prostate by ultrasound guidance. The injection of WST11 is then performed with light illumination of the specific targeted area. Current data report 83% negative biopsies 6 months after treatment with good tolerance of the treatment. However, VTP still needs to be evaluated.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.